HPV Vaccination and Screening: Australia’s Path to Cervical Cancer Elimination

Australia Nears Cervical Cancer Elimination, Faces Setbacks in prevention

Australia is on the verge of eliminating cervical‌ cancer thanks to decades of investment in⁣ human papillomavirus (HPV) vaccination and cervical cancer screening programs, according to a report released‌ by the NHMRC​ Center‌ of Research Excellence in Cervical Cancer Control. Tho,declining vaccination and screening rates pose a threat ‍to this progress.

decades of Progress

the ​National Cervical Cancer Screening Program, launched in 1991, initially focused on regular Pap tests (cytology) to identify ‍and treat early cell changes before they developed into cancer. This program reduced cervical‍ cancer cases and deaths by approximately ⁢50%, according to the American Sexual Health Association.

In 2007, Australia implemented the world’s first‌ national HPV vaccination program. This led to a significant decrease in HPV infection rates and the incidence of cervical pre-cancers.

Further improvements came in 2017 with the transition from Pap ‌tests to HPV⁢ tests, specifically‌ targeting ​HPV types 16‌ and 18, responsible for the majority of cervical cancers. individuals testing positive receive closer monitoring from healthcare providers, a change projected to lower‌ cervical cancer rates by an additional 20-30%.

In ⁣2018, Australia ‍introduced a nine-valent HPV vaccine, expanding protection to nine cancer-causing ⁣HPV types,⁤ compared to the four types⁣ covered in earlier versions. Both versions of the vaccine protected against types​ 16 and 18.

The Plan to End Cervical Cancer

Building on these advancements, Australia launched a national cervical ‌cancer elimination strategy in 2023. The plan established five-year goals:

• Vaccinate 90% of girls and boys.
• Screen 70% of women aged⁣ 25-75 every five ⁤years.
• Treat 95% of detected pre-cancers and cancers.

The recent report indicates Australia is making ‍strides toward achieving these objectives.